T he ability to achieve a high level of selectivity for a specific biological target is a key requirement for the generation of effective therapeutic agents and molecular probes. This endeavor can be quite challenging. Pockets that bind enzyme cofactors, hormones, and other key regulatory molecules are often highly conserved among protein family members that control diverse biological processes. However, our increasingly better understanding of the molecular recognition of protein-smallmolecule interactions is beginning to allow the design of selective compounds that can target a single subtype among highly structurally similar members of protein families (1, 2) . In this issue of ACS Chemical Biology, Ocasio and Scanlan (3) report on the use of a rational design approach to identify the first specific agonist of thyroid hormone receptor (TR)-alpha (TR␣). This agonist has profound effects on TR␣-mediated metamorphosis of Xenopus laevis, and it represents an important new molecular probe for dissecting signaling pathways controlled by this nuclear receptor (NR).
Members of the NR superfamily of transcription factors share conserved ligand binding domains (LBDs). By binding small molecules, NRs play key roles in embryonic development, cellular differentiation, metabolism, and cell death. Many of these proteins represent major drug targets, and selective therapeutic agents targeting specific NR subtypes have the potential to revolutionize the treatment of diseases of the endocrine system (4). One such NR is the TR, which comprises two related subtypes, TR␣ and TR␤, encoded by two different genes (5) . The LBDs of these subtypes are ϳ75% identical in amino acid sequence. The thyroid hormone 3,5,3=-triiodo-L-thyronine ( Figure 1, T 3 , 1) binds the LBDs of both subtypes with high affinity (K d ϭ 0.06 nM) (6) . Consequently, T 3 influences numerous physiological parameters, including growth, development, homeostasis, metabolism, heart rate, lipid levels, and mood (7). Pharmacological treatment with thyroid hormone has the potential to control body weight and lower cholesterol and triglycerides (8) . However, this therapeutic approach has been plagued by side effects of hyperthyroidism, such as elevated heart rate and arrhythmia (9) . Studies of patients resistant to thyroid hormone and knockout of the TR subtypes in mice have revealed that TR␣ mediates the effect of thyroid hormone on heart rate, whereas TR␤ affects other responses to this hormone (10) . Because of the potential of TR␤ as a target of obesity, hyperlipidemia, depression, and osteoporosis, selective TR␤ agonists are of significant interest as therapeutic agents (11) . However, the design of compounds selective for only one of the two TR subtypes is difficult. The residues that define the hydrophobic ligand binding pockets (LBPs) of TR␣ and TR␤ differ by only one amino acid; Ser277 in TR␣ is replaced by Asn331 in TR␤. Despite these similarities, TR␤-selective ligands such as GC-1 (2) (12) and compound 3 (Figure 1 ) (13) A B S T R A C T Small molecules that function as highly selective agonists and antagonists of cellular receptors comprise some of the most valuable therapeutic agents and molecular probes. A recent paper describes the design, synthesis, and evaluation of CO23, the first potent and specific agonist of thyroid hormone receptor-alpha (TR␣), a member of the nuclear receptor (NR) superfamily of transcription factors. Together with previously reported TR␤-selective agonists such as GC-1, these compounds represent powerful new tools for studying gene expression, signaling, differentiation, and development controlled by this important NR.
Point of VIEW compound 3 (13) and TR␤ bound to T 3 (1) (14) is shown (Figure 2) .
Selective TR␣ agonists are of significant interest as molecular probes of TR signaling pathways. On page 585 of this issue of ACS Chemical Biology, Ocasio and Scanlan (3) describe the first such TR␣-selective thyromimetic, termed CO23 (Figure 1, 4) . CO23 (4) is a selective TR␣ agonist despite binding to both of the purified TR subtypes with equal affinity. This similarity in affinity is perhaps not surprising given that the LBPs are identical except for the single Ser277 to Asn331 substitution. In contrast, GC-1 (12) and compound 3 (13) are selective agonists of TR␤ because they bind substantially more tightly to this protein subtype. Several available X-ray structures of TRs bound to ligands (13) (14) (15) (16) show that the selective binding of GC-1 (2) and compound 3 to TR␤ appears to result from participation of the carboxylate moiety in a hydrogen bonding network that includes the TR␤ Asn331 residue.
When evaluated against TRs expressed in mammalian cells, CO23 (4) selectively activates gene expression controlled by TR␣. Previous studies of related estrogen receptors (17, 18) show that this selectivity may arise from subtle differences in the induced conformations of amino acid side chains that define the LBP. Minor effects on amino acid side chains can influence the dynamics of the conformationally mobile helix-12, the most carboxy-terminal helix of NR LBDs (19) . Perturbation of helix-12 can affect the recruitment of coactivator proteins to the LBD, potentiate interactions with the transcriptional machinery, and regulate gene expression.
Because of its selectivity for TR␣, CO23 (4) has unique effects on TR signaling in vivo. When tadpoles of the frog X. laevis are treated with CO23 (4), this compound triggers only part of the developmental program that regulates metamorphosis; hind limbs of tadpoles grow, but other developmental changes are not activated. These changes include resorption of the head and tail observed upon treatment with the pan-agonist T 3 (1) or the TR␤-selective agonist GC-1 (2) (20) . Moreover, sequential treatment of tadpoles with CO23 (4) followed by GC-1 (2) revealed that these isoform-selective agonists can be used for temporal control of tadpole morphogenesis; the proper sequence of activation of the two TR subtypes is critical for correct execution of the developmental program. Furthermore, it was also confirmed by realtime PCR analysis of gene expression that selective activation of TR␣ in vivo by CO23 (4) is controlled by this TR subtype.
GC-1 (2) and CO23 (4) represent members of a growing family of small molecules that affect development or cellular differentiation by interacting with defined molecular targets. Among the compounds known to affect NRs in this way, BMS493, a pan-antagonist of the retinoic acid receptors alpha, beta, and gamma, affects hindbrain patterning in chick embryos (21) . Rosiglitazone and other members of the thiazolidinedione family of antidiabetic drugs can control the differentiation of adipocytes by functioning as selective agonists of the peroxisome proliferator-activated receptorgamma (PPAR␥) (22) . Conversely, the selective PPAR␥ antagonist T0070907 inhibits differentiation of adipocytes (23) . Other compounds that affect development and differentiation through well-characterized mechanisms include purmorphamine (24, 25) and cyclopamine (26) . These compounds function as agonists and antagonists, respectively, of Smoothened, a key regulator of the Hedgehog signaling pathway. Other examples of the use of chemical genetics to probe developmental biology have also been reviewed (27) .
Activation of gene expression mediated by the genomic effects of TR␣ and TR␤ can now be dissociated in vivo through the use of specific small molecules. This chemicalgenetics approach provides new tools to elucidate the complex biology regulated by NRs. However, in addition to their genomic effects, TRs and many other NRs activate distinct nongenomic signaling pathways (28) . Given the previous achievements of using small molecules to separate genomic from nongenomic actions of estrogen receptors (29, 30) , identifying compounds that isolate these specific functions of TR subtypes to provide even finer resolution should be possible. Further development of this strategy has the potential to lead to highly selective therapeutic agents for various life-threatening diseases and to powerful molecular probes of signaling pathways yet to be fully elucidated.
